Figure 5.
Change in liver fat as measured by MR Spectroscopy (ΔHCL/W%) in the tesamorelin and placebo groups in a 6 month investigation of the effects of tesamorelin on liver fat in HIV-infected subjects with abdominal adiposity (82). Medians with bars for IQR are shown.